Skip to main content

Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Immunovant, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
6 insiders, $1.12M in total
Insiders trading
6
Net value
−$1.12M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Immunovant, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Immunovant, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Van Tuyl ChristopherChief Legal Officer176,545Sep 25, 20268
Pande AtulDirector116,731Aug 28, 20266
Gloria MelanieChief Operating Officer219,301Aug 21, 20268
Girao TiagoChief Financial Officer240,798Jul 24, 20264
Stout Jay SChief Technology Officer205,341Jul 24, 202610
Venker EricChief Executive Officer254,280Jul 6, 20263
Fromkin Andrew J.Director74,382May 29, 20263
Susman Robert GrahamDirector36,394May 1, 20262
Torti FrankDirector1,009,228Apr 9, 20261
Bauer JakeDirector38,896Apr 9, 20261
Hughes Douglas J.Director134,653Apr 9, 20262
Roivant Sciences Ltd.Director, 10% Owner113,317,007Dec 12, 20251
Geffner MichaelChief Medical Officer217,958Oct 24, 20252
Salzmann PeterChief Executive Officer1,178,191Apr 17, 20250
Barnett Eva ReneeChief Financial Officer396,774Apr 17, 20250
Migausky George VDirector137,251Apr 3, 20250
Macias William L.Chief Medical Officer357,353Feb 21, 20250
Levine Mark S.Chief Legal Officer319,228Nov 22, 20240
Butchko Julia G.Chief Development Officer440,959Aug 23, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 25, 2023 (view filing)Aug 241 dayButchko Julia G.Chief Development OfficerSSale−12.3K$20.30−$250.4K−2.9%416.3K after2 lots
Aug 25, 2023 (view filing)Aug 241 dayBarnett Eva ReneeChief Financial OfficerSSale−14.4K$20.30−$292.0K−4.1%335.5K after2 lots
Aug 25, 2023 (view filing)Aug 241 dayLevine Mark S.Chief Legal OfficerSSale−12.3K$20.30−$249.4K−3.8%314.5K after2 lots
Sep 1, 2023 (view filing)Aug 302 daysSalzmann PeterChief Executive OfficerSSale−56.8K$22.02−$1.25M−5.5%970.0K after2 lots
Oct 4, 2023 (view filing)Oct 22 daysRoivant Sciences Ltd.Director, 10% OwnerPPurchaseCommon Stock, $0.0001 par value per share+1.53M$38.00+$58.0M+1.9%79.8M after
Oct 6, 2023 (view filing)Oct 51 daySalzmann PeterChief Executive OfficerSSale−5.24K$36.24−$189.9K−0.5%964.7K after2 lots
Oct 6, 2023 (view filing)Oct 51 dayButchko Julia G.Chief Development OfficerSSale−1.74K$36.24−$62.9K−0.4%414.5K after2 lots
Oct 11, 2023 (view filing)Oct 101 dayBarnett Eva ReneeChief Financial OfficerSSale−4.56K$36.92−$168.2K−1.4%330.9K after
Oct 20, 2023 (view filing)Oct 191 dayMacias William L.Chief Medical OfficerSSale−530$36.80−$19.5K−0.2%336.9K after
Oct 27, 2023 (view filing)Oct 252 daysLevine Mark S.Chief Legal OfficerSSale−4.11K$34.66−$142.3K−1.3%310.4K after
Nov 24, 2023 (view filing)Nov 222 daysLevine Mark S.Chief Legal OfficerSSale−3.25K$32.78−$106.6K−1.0%307.1K after2 lots
Nov 24, 2023 (view filing)Nov 222 daysMacias William L.Chief Medical OfficerSSale−3.27K$32.78−$107.0K−1.0%333.6K after2 lots
Nov 24, 2023 (view filing)Nov 222 daysButchko Julia G.Chief Development OfficerSSale−3.27K$32.78−$107.0K−0.8%411.3K after2 lots
Nov 24, 2023 (view filing)Nov 222 daysBarnett Eva ReneeChief Financial OfficerSSale−4.05K$32.78−$132.9K−1.2%326.9K after2 lots
Nov 24, 2023 (view filing)Nov 222 daysSalzmann PeterChief Executive OfficerSSale−16.2K$32.78−$531.6K−1.7%948.5K after2 lots
Dec 5, 2023 (view filing)Dec 14 daysMigausky George VDirectorSSale−12.7K$39.73−$504.6K−10.4%109.8K after3 lots10b5-1
Dec 5, 2023 (view filing)Dec 14 daysPande AtulDirectorSSale−12.3K$39.73−$490.7K−12.9%83.2K after3 lots10b5-1
Dec 5, 2023 (view filing)Dec 14 daysFromkin Andrew J.DirectorSSale−12.3K$39.73−$490.7K−12.2%88.7K after3 lots10b5-1
Jan 9, 2024 (view filing)Jan 54 daysSalzmann PeterChief Executive OfficerSSale−3.82K$38.59−$147.6K−0.4%944.7K after
Jan 9, 2024 (view filing)Jan 54 daysButchko Julia G.Chief Development OfficerSSale−1.30K$38.59−$50.1K−0.3%410.0K after
Jan 12, 2024 (view filing)Jan 111 dayBarnett Eva ReneeChief Financial OfficerSSale−3.52K$41.83−$147.0K−1.1%323.4K after2 lots
Jan 19, 2024 (view filing)Jan 181 dayMacias William L.Chief Medical OfficerSSale−424$41.03−$17.4K−0.1%333.2K after
Jan 29, 2024 (view filing)Jan 263 daysGeffner MichaelChief Medical OfficerSSale−10.1K$37.92−$383.0K−10.1%89.9K after2 lots
Jan 29, 2024 (view filing)Jan 263 daysLevine Mark S.Chief Legal OfficerSSale−3.03K$37.92−$114.8K−1.0%304.1K after2 lots
Feb 23, 2024 (view filing)Feb 221 daySalzmann PeterChief Executive OfficerSSale−13.5K$36.15−$486.4K−1.4%931.2K after
Feb 23, 2024 (view filing)Feb 221 dayButchko Julia G.Chief Development OfficerSSale−2.15K$36.15−$77.6K−0.5%407.8K after
Feb 23, 2024 (view filing)Feb 221 dayMacias William L.Chief Medical OfficerSSale−2.22K$36.15−$80.3K−0.7%331.0K after
Feb 23, 2024 (view filing)Feb 221 dayLevine Mark S.Chief Legal OfficerSSale−2.13K$36.15−$77.1K−0.7%302.0K after
Feb 23, 2024 (view filing)Feb 221 dayBarnett Eva ReneeChief Financial OfficerSSale−2.93K$36.15−$105.9K−0.9%320.4K after
Apr 10, 2024 (view filing)Apr 91 daySalzmann PeterChief Executive OfficerSSale−4.81K$31.18−$149.9K−0.4%1.09M after
Apr 10, 2024 (view filing)Apr 91 dayButchko Julia G.Chief Development OfficerSSale−1.05K$31.18−$32.8K−0.2%461.7K after
Apr 10, 2024 (view filing)Apr 91 dayBarnett Eva ReneeChief Financial OfficerSSale−3.69K$31.18−$115.0K−1.0%371.7K after
Apr 19, 2024 (view filing)Apr 172 daysSalzmann PeterChief Executive OfficerSSale−34.1K$29.06−$990.3K−3.1%1.05M after2 lots
Apr 19, 2024 (view filing)Apr 172 daysButchko Julia G.Chief Development OfficerSSale−10.1K$29.06−$293.9K−2.2%451.6K after2 lots
Apr 19, 2024 (view filing)Apr 172 daysBarnett Eva ReneeChief Financial OfficerSSale−12.3K$29.06−$356.0K−3.3%359.5K after2 lots
Apr 19, 2024 (view filing)Apr 172 daysMacias William L.Chief Medical OfficerSSale−8.28K$29.06−$240.6K−2.1%377.6K after4 lots
Apr 19, 2024 (view filing)Apr 172 daysLevine Mark S.Chief Legal OfficerSSale−9.83K$29.06−$285.6K−2.8%347.1K after2 lots
Apr 26, 2024 (view filing)Apr 242 daysLevine Mark S.Chief Legal OfficerSSale−3.96K$28.90−$114.5K−1.1%343.2K after
Apr 26, 2024 (view filing)Apr 242 daysStout Jay SChief Technology OfficerSSale−7.24K$28.90−$209.2K−4.7%147.7K after
Apr 26, 2024 (view filing)Apr 242 daysGeffner MichaelChief Medical OfficerSSale−3.26K$28.90−$94.2K−2.3%141.6K after
May 24, 2024 (view filing)May 222 daysLevine Mark S.Chief Legal OfficerSSale−3.24K$29.65−$96.1K−0.9%339.9K after
May 24, 2024 (view filing)May 222 daysMacias William L.Chief Medical OfficerSSale−3.25K$29.65−$96.3K−0.9%374.4K after
May 24, 2024 (view filing)May 222 daysButchko Julia G.Chief Development OfficerSSale−3.25K$29.65−$96.3K−0.7%448.4K after
May 24, 2024 (view filing)May 222 daysSalzmann PeterChief Executive OfficerSSale−16.2K$29.65−$479.2K−1.5%1.04M after
May 24, 2024 (view filing)May 222 daysBarnett Eva ReneeChief Financial OfficerSSale−4.04K$29.65−$119.8K−1.1%355.4K after
Jul 10, 2024 (view filing)Jul 91 daySalzmann PeterChief Executive OfficerSSale−4.62K$28.06−$129.6K−0.4%1.03M after
Jul 10, 2024 (view filing)Jul 91 dayButchko Julia G.Chief Development OfficerSSale−1.53K$28.06−$42.8K−0.3%446.9K after
Jul 10, 2024 (view filing)Jul 91 dayBarnett Eva ReneeChief Financial OfficerSSale−4.75K$28.06−$133.2K−1.3%350.7K after
Jul 19, 2024 (view filing)Jul 172 daysSalzmann PeterChief Executive OfficerSSale−8.69K$29.69−$257.9K−0.8%1.02M after2 lots
Jul 19, 2024 (view filing)Jul 172 daysButchko Julia G.Chief Development OfficerSSale−2.87K$29.69−$85.1K−0.6%444.0K after2 lots